Form D · Other Technology
Cambium Biomaterials, Inc.
El Segundo, CA · CIK 0001883516
Offering snapshot reported Dec 4, 2025 · SEC filing
- Reported sold
- $94.4M Offering amount: $101M
- Investors reported
- 33 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 18, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 4, 2025 | Initial | $94,366,494 | No comparison | 33 | SEC filing |
| Nov 14, 2023 | Initial | $17,364,116 | No comparison | 16 | SEC filing |
| Sep 17, 2021 | Initial | $8,012,877 | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-565703
Source: Form D, filed Dec 4, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Tim Gardner | Executive |
| Francisco Gimenez | Director |
| James Griffin | Executive |
| Andrew Guenthner | Executive |
| Stephan Herrera | Executive |
| Nic Madren | Executive |
| Christopher Pederson | Director |
| Eliot Pence | Executive |
| Brett Schneider | Director |
| Simon Waddington | Director, Executive |
Issuer details
Industry: Other Technology (See others in industry)
Address:
111 Maryland Street
El Segundo, CA, 90245
El Segundo, CA, 90245